Al18F-NOTA-LM3 PET/CT imaging for pheochromocytoma and paraganglioma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The study compares a new 18F-labeled somatostatin receptor antagonist (Al18F-NOTA-LM3) with the current 68Ga-DOTATATE PET/CT approach for imaging pheochromocytoma and paraganglioma. Participants aged 18–80 with suspected or confirmed PPGL will undergo PET/CT imaging with both tracers and the images will be compared for lesion detection, biodistribution, and image quality. Al18F-NOTA-LM3 is expected to offer advantages in production yield, image resolution, and logistics because of the longer half-life of 18F, and preliminary data support its safety and targeting. The comparison is conducted at a single center (Peking Union Medical College Hospital) with predefined exclusion criteria such as severe liver/renal dysfunction, pregnancy, breastfeeding, or inability to undergo PET/CT.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients aged 18 to 80 years.
* Suspected or confirmed PPGL patients.

Exclusion Criteria:

* Combined with other types of tumors.
* Severe liver or renal dysfunction (ALT/AST≥5 ULN, GFR\<30ml/min).
* Pregnant or breast-feeding women.
* Inability to perform PET/CT scans.

Where it's running

• Peking Union Medical College Hospital
  Beijing, Beijing Municipality, China Recruiting

Study contacts

• Study coordinator: Hongli Jing
• Email: annsmile1976@sina.com
• Phone: 18600586399

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using a new imaging agent to detect various cancers

  This study is testing a new imaging agent to see if it can better detect certain cancers in adults compared to standard imaging methods.

  Recruiting Phase 2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT06503146

• Adrenal Diseases in Modena: A Patient Registry at Modena University Hospital

  This study collects medical histories and treatment data from patients with adrenal diseases to see how they are diagnosed and managed in Modena.

  Recruiting Azienda Ospedaliero-Universitaria di Modena · Modena, Modena · NCT07920198

• Belzutifan as a preoperative option for pheochromocytoma/paraganglioma

  This study tests whether belzutifan can safely help prepare patients with pheochromocytoma or paraganglioma for surgery and reduce catecholamine-related effects.

  Recruiting Phase 4 Xiangya Hospital of Central South University · Changsha, Hunan · NCT07907341

• Belzutifan and catecholamine metabolism in pheochromocytoma/paraganglioma

  This study tests whether Belzutifan can change how catecholamines are produced and broken down in adults with pheochromocytoma or paraganglioma.

  Recruiting Phase 2 Cambridge University Hospitals NHS Foundation Trust · Cambridge, Cambridgeshire · NCT07680205

• Real-world belzutifan outcomes and pharmacogenetics in von Hippel-Lindau syndrome

  This study will test belzutifan in people aged 14 and older with VHL syndrome to see how well it controls VHL-associated tumors, what side effects occur, and how genetic factors affect response.

  Recruiting Phase 2 AC Camargo Cancer Center · São Paulo, São Paulo · NCT07167329

• Using Ivocizumab to treat various advanced rare tumors

  This study is testing if a new treatment called Ivocizumab can help people with different types of advanced rare tumors feel better and live longer.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT06683846

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.